Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes will present 26 abstracts at SLEEP 2026, headlined by an oral presentation of detailed positive results from the Vibrance-2 Phase 2 study of alixorexton in narcolepsy type 2. The company will also share baseline characteristics from the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia, where positive topline results were recently announced.
Key figures
- Drug Name
- Alixorexton
- Phase Of Trial
- Phase 2
- Abstract count
- 26
- Vibrance 2 patients
- 93
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.